GURUFOCUS.COM » STOCK LIST » USA » NAS » C4 Therapeutics Inc (NAS:CCCC) » Definitions » Total Current Assets
Switch to:

C4 Therapeutics (NAS:CCCC) Total Current Assets

: $287.56 Mil (As of Dec. 2022)
View and export this data going back to 2020. Start your Free Trial

Total current assets includes Cash And Cash Equivalents, Accounts Receivable, Total Inventories, and Other Current Assets. C4 Therapeutics's total current assets for the quarter that ended in Dec. 2022 was $287.56 Mil.


C4 Therapeutics Total Current Assets Historical Data

The historical data trend for C4 Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4 Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Total Current Assets
123.53 96.77 381.01 325.69 287.56

C4 Therapeutics Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Total Current Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 325.69 302.95 318.37 325.46 287.56

C4 Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

C4 Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

C4 Therapeutics's Total Current Assets for the quarter that ended in Dec. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


C4 Therapeutics  (NAS:CCCC) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

C4 Therapeutics's Liquidation Value for the quarter that ended in Dec. 2022 is

Liquidation value
= Cash And Cash Equivalents-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=276.153-141.606+0.75 * 1.473+0.5 * 0
=135.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


C4 Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of C4 Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


C4 Therapeutics (NAS:CCCC) Business Description

C4 Therapeutics logo
Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 200, Watertown, MA, USA, 02472
C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.
Executives
Laura Bessen director 4747 EXECUTIVE DRIVE, SUITE 1150, SAN DIEGO CA 92121
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Scott N Boyle officer: Chief Business Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Kelly Schick officer: Chief People Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Utpal Koppikar director C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Lauren White officer: Chief Financial Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Glenn Dubin director C/O HIGHBRIDGE CAPITAL MANAGEMENT, LLC, 40 WEST 57TH STREET, 32ND FLOOR, NEW YORK NY 10019
Marc A Cohen director, 10 percent owner, officer: Chief Executive Officer 1000 WILSON BLVD. #1800, ARLINGTON VA 22209
Alain J Cohen director, 10 percent owner 7255 WOODMONT AVE, BETHESDA MD 20814
Elena Prokupets director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Kenneth Carl Anderson director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Malcolm Salter director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Jolie Siegel officer: Chief Legal Officer C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Stewart Fisher officer: Chief Scientific Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Laura Jean Wahlberg officer: See Remarks C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472

C4 Therapeutics (NAS:CCCC) Headlines

From GuruFocus

Other Sources